華魯恒升(600426.SH):擬投建20萬噸/年二元酸項目等
格隆匯5月22日丨華魯恒升(600426.SH)公佈,擬啟動新一批項目建設,包括:酰胺原料優化升級項目、20萬噸/年二元酸項目。根據可行性研究報吿測算,上述兩個項目預計總投資為17億元,其中:酰胺原料優化升級項目8.33億元、二元酸項目8.67億元,項目建設資金由公司自有資金和銀行貸款解決。
酰胺原料優化升級項目建成投產後預計年均實現營業收入16.74億元。20萬噸/年二元酸項目建成投產後預計年均實現營業收入6.24億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.